Regeneron Pharmaceuticals | REGN - Sales Revenues


Regeneron Pharmaceuticals reported $5.12B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Agenus USD 33.7M 500K Mar/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.4B 300M Sep/2026
Astellas Pharma JPY 629.95B 10.96B Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
J&J USD 25.4B 89M Sep/2026
Kyowa Hakko Kirin JPY 121.3B 23.86B Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Moderna USD 1.31M 98.69M Sep/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Novartis USD 15.03B 1.92B Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 12.3B 160M Jun/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Teva Pharmaceutical Industries USD 4.37B 8.3B Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
United Therapeutics USD 832.5M 49.2M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026